Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults
Clinical trial NCT06302374 · COMPLETED
Trial details
- NCT number
- NCT06302374
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-04
- Primary completion
- 2023-11-01
- Enrollment
- 202
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.